Profusa Inc. (PFSA)
PFSA trades on Nasdaq in Health Care, Medical/Dental Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2024-12-31, https://www.sec.gov/Archives/edgar/data/1859807/000121390026044046/0001213900-26-044046-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2024-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PFSA on Nasdaq |
| Sector | Health Care |
| Industry | Medical/Dental Instruments |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001859807 |
| SEC industry code | Surgical & Medical Instruments & Apparatus |
| Incorporated in | DE |
Financials · 2024
| Line | Value |
|---|---|
| Revenue | $100K |
| Net income | -$9.2M |
| Operating income | -$4.5M |
| Net margin | -9230.0% |
| Operating margin | -4500.0% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $191K |
| Total assets | $3.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "As of September 30, 2026, there continue to be factors which raise substantial doubt about the Company's ability to continue as a going concern within one year from the date the condensed consolidated financial statements are issued." | 10-Q 2026-11-13 |
| Cash and burn | $719K cash; operating cash flow -$5.1M a quarter. | Report 2026-06-30 |
| Shares outstanding | 5,681,947 (2026-11-13); 65,680,958 a year earlier; 6,167,882 three years earlier. 1y figure adjusted for splits (1-for-7500 overall); 3y figure adjusted for splits (1-for-7500 overall). | Cover page 2026-11-13 |
| Reverse splits, 3 years | 3; latest 1-for-4 on 2026-08-17 | Source 2026-08-17 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 3 (8-K item 3.01) | 8-K 2026-08-31 |
| Delisting | 25-NSE filed | 25-NSE 2025-05-22 |
| Auditor | CBIZ CPAs P.C., San Francisco, California, United States; changed auditors 2 times in 24 months | 8-K 4.01 2026-10-09 |
| Late filings, 12 months | 2 NT notices | NT 10-Q 2026-08-14 |
| Insider trades, 12 months | Bought $37K, sold $153K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
| Market cap check | The listing's market cap implies 605,647 shares at the 2026-11-13 price; the latest SEC cover count is 5,681,947 as of 2026-11-13. One of the two share counts is stale. | Nasdaq screener and SEC cover page |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$8.8M | -$2.6M | $719K | $17.0M | Needs four quarters | 10-Q 2026-08-19 |
| Q1 2026 2026-03-31 | Not filed | -$3.5M | -$2.6M | $375K | $16.6M | Needs four quarters | 10-Q 2026-08-19 |
| Q4 2025 2025-12-31 | Not filed | -$8.6M | -$5.1M | $1.8M | $10.8M | Needs four quarters | 10-K 2026-04-15 |
| Q3 2025 2025-09-30 | Not filed | -$22.2M | -$10.0M | $3.0M | $19.7M | Needs four quarters | 10-Q 2025-11-19 |
| Q2 2025 2025-06-30 | Not filed | -$2.3M | -$589K | $39K | $1.9M | Needs four quarters | 10-Q 2026-08-19 |
| Q1 2025 2025-03-31 | Not filed | -$2.7M | -$537K | $19K | $3.4M | Needs four quarters | 10-Q 2026-08-19 |
| Q4 2024 2024-12-31 | $0 | -$2.3M | -$238K | $191K | $48.8M | $100K | 10-K 2026-04-15 |
| Q3 2024 2024-09-30 | $75K | -$2.5M | -$1.2M | $533 | $3.4M | Needs four quarters | 10-Q 2025-11-19 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS SUPPLEMENT | 424B3 | 2026-07-07 |
| Latest annual report ANNUAL REPORT | 10-K | 2026-04-15 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-11-13 |
| Latest current report CURRENT REPORT | 8-K | 2026-11-06 |
| Latest proxy PROXY STATEMENT | PRE 14A | 2026-11-10 |
Source: SEC EDGAR submissions feed, 326 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -16.1% |
| 1 month | -65.0% |
| 3 months | -88.2% |
| Year to date | -99.9% |
| 1 year | -100.0% |
| From 52-week high | -100.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medical/Dental Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| VJET | Flyte Aviation Inc. | $0.4430 | -10.11% | $931K |
| NXGL | NexGel Inc | $3.93 | +2.08% | $1.9M |
| AMIX | Autonomix Medical Inc. | $1.10 | -19.71% | $2.2M |
| CODX | Co-Diagnostics Inc. | $0.2249 | -13.03% | $2.4M |
| BJDX | Bluejay Diagnostics Inc. | $2.29 | -12.26% | $2.6M |
| ICCM | IceCure Medical Ltd. | $0.7601 | +4.12% | $2.6M |
| IVF | INVO Fertility Inc. | $2.40 | -7.69% | $2.8M |
| VVOS | Vivos Therapeutics Inc. | $0.0822 | -16.12% | $2.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier